Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 18 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

33%

6 trials in Phase 3/4

Results Transparency

50%

5 of 10 completed with results

Key Signals

5 with results100% success

Data Visualizations

Phase Distribution

8Total
Not Applicable (2)
P 3 (6)

Trial Status

Completed10
Recruiting4
Not Yet Recruiting2
Active Not Recruiting1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT07529756Not Yet Recruiting

The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry

NCT06998745Not ApplicableRecruitingPrimary

The Impact of MTM Model on the Efficacy and Safety of Anticoagulant Therapy in Postoperative Colorectal Cancer Patients

NCT06349291RecruitingPrimary

Venous Thrombosis After Removal of Central Venous Catheter

NCT06288906RecruitingPrimary

Acute and Subacute Iliofemoral and/or Caval Deep Vein Thrombosis: Evaluation of Mechanical Thrombectomy Systems

NCT05396157Active Not RecruitingPrimary

Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study

NCT06440044CompletedPrimary

Recurrence and Bleeding in Colorectal Cancer Patients With Cancer-associated Venous Thrombembolism

NCT06094387Recruiting

The Use of Thrombin Generation Assay in Detection of Central Line Related Thrombosis (CRT) in Critically Ill Patients

NCT06149533Phase 3Not Yet RecruitingPrimary

Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients

NCT04503135Completed

Catheter Associated Asymptomatic Thrombosis in Intensive Care Unit

NCT05710705Not ApplicableUnknown

Bioimpedance Measurement of Abdominal Free Flaps During Arterial and Venous Weaning in Breast Reconstruction

NCT00320398Phase 3CompletedPrimary

Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)

NCT01444612CompletedPrimary

Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery

NCT00312013Phase 3CompletedPrimary

Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer

NCT00443053Phase 3CompletedPrimary

Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

NCT00911157Phase 3CompletedPrimary

The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients

NCT00843492Phase 3CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery

NCT01064362CompletedPrimary

Hemorrhage Risk Prescribed Arixtra

NCT01691495CompletedPrimary

ARIXTRA® Adherence in SVT Patients.

Showing all 18 trials

Research Network

Activity Timeline